Immune Landscape of Renal Cell Carcinoma

Dear Colleagues,

This Special Issue, entitled “Immune Landscape of Renal Cell Carcinoma”, recognizes the unique history of renal cell carcinoma (RCC) as a solid tumor responsive to immune-based treatments. Immune checkpoint inhibitors (ICIs) are now firmly established as part of front-line treatment regimens for advanced disease and associated with improved response rates, durability of disease control, and overall survival. Yet, despite these important gains, clinical outcomes remain heterogenous. Primary or acquired treatment resistance is observed in most patients, with the predominant result being that metastatic disease remains largely incurable.

The aim of this Special Issue is to broadly address both the advantages and disadvantages of ICIs and other immune-based therapies for advanced RCC, exploring clinical outcomes derived from the use of standard-of-care and novel emerging immunotherapy agents and combinations; translational studies including biomarker discovery, tumor antigen identification, and the investigation of mechanisms for tumor resistance and escape; and the preclinical modeling of RCC-directed immunotherapy.

For this Special Issue, we welcome the submission of review papers and original research articles.

We look forward to receiving your contributions.

Dr. Scott S. Tykodi
Dr. Yuexin Xu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• renal cell carcinoma
• solid tumor
• immunotherapy
• immune checkpoint inhibitor
• T cell
• tumor microenvironment
• biomarkers
• tumor antigen
• immune surveillance